Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Pitt Hopkins Syndrome
NCT07150026Phase 1Recruiting
- Sponsor
- Unravel Biosciences
- Start
- Mar 2026
- Primary completion
- Dec 2026
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind trial of vorinostat in Pitt-Hopkins syndrome (PTHS) (3 arms), sponsored by Unravel Biosciences. Primary endpoints: Frequency of treatment-related adverse events at 20 weeks, Drug tolerability as measured by number of treatment discontinuations at 20 weeks and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
vorinostat
03
Conditions
Pitt-Hopkins syndrome (PTHS)
Beyond the preview
Go deeper on NCT07150026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07150026.